title: Carcinogenetic process in gallbladder mucosa with pancreaticobiliary maljunction (Review).
abstract: Pancreaticobiliary maljunction (PBM) is a congenital anomaly with a high incidence of biliary tract carcinoma. Pathological findings strongly suggest that there is a hyperplasia-dysplasia-carcinoma sequence in carcinogenesis of PBM. A molecular biological analysis revealed high incidence of cellular proliferation activating factors such as TGF-alpha, COX-2 from the hyperplasia stage. In addition, cellular proliferative activity including BrdU, AgNOR, PCNA, and Ki-67 was significantly higher in regular gallbladder mucosa without PBM. Furthermore, a high incidence of K-ras gene mutation could be seen in hyperplasia (13-63%) and microsatellite instability could be observed in 60% of all cases in dysplasia. In cancerous lesions, a high rate of overexpression of cyclin D1, beta-catenin, p53, as well as p53 gene mutation has been recognized. These results suggest that a multistep carcinogenetic process contributes to the carcinogenesis of PBM, similar to that of other cancers. In addition, after preventive operation with resection of the extrahepatic bile duct is performed, carcinogenesis in the remnant biliary tract or pancreatic duct is rarely found. Whether the carcinogenesis is a result of the accumulation of genetic alteration from shortly after birth, or a result of regurgitation of gastrointestinal juice due to hepaticoenterostomy, remains unknown. Since a high frequency of COX-2 is positive in PBM, COX-2 inhibitors such as NSAIDs may play an important role in preventing carcinogenesis.
authors.affiliation: Department of Surgery, Tokyo Medical University, Tokyo 160-0023, Japan. akibobo@hotmail.com
authors.forename: Akihiko
authors.initials: A
authors.lastname: Tsuchida
authors.forename: Takao
authors.initials: T
authors.lastname: Itoi
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Aoki
authors.forename: Yasuhisa
authors.initials: Y
authors.lastname: Koyanagi
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D001660:Biliary Tract Diseases / Q000150:complications / Q000473:pathology*; D001661:Biliary Tract Neoplasms / Q000209:etiology / Q000473:pathology*; D002453:Cell Cycle; D002455:Cell Division; D003135:Common Bile Duct / Q000002:abnormalities* / Q000473:pathology*; D019938:Cyclin D1 / Q000378:metabolism; D051546:Cyclooxygenase 2; D003598:Cytoskeletal Proteins / Q000378:metabolism; D005704:Gallbladder / Q000473:pathology*; D016158:Genes, p53; D011905:Genes, ras; D006801:Humans; D006965:Hyperplasia; D007527:Isoenzymes / Q000378:metabolism; D019394:Ki-67 Antigen / Q000096:biosynthesis; D008565:Membrane Proteins; D009092:Mucous Membrane / Q000473:pathology*; D009154:Mutation; D011183:Postoperative Complications; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D015534:Trans-Activators / Q000378:metabolism; D051176:beta Catenin
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; C495270:CTNNB1 protein, human; D003598:Cytoskeletal Proteins; D007527:Isoenzymes; D019394:Ki-67 Antigen; D008565:Membrane Proteins; D018809:Proliferating Cell Nuclear Antigen; D015534:Trans-Activators; D051176:beta Catenin; D019938:Cyclin D1; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases